In breast cancer, HBXIP recruits p300 to acetylate HOXB13 at K277, stabilizing the protein and preventing its CMA-mediated degradation, which drives ERα-dependent proliferation [60, 61], while acetylation of MST1 stabilizes its tumor-suppressive role in the Hippo pathway, and its dysregulation facilitates cancer initiation [62]. Here, EP300 is linked to breast carcinoma.